G1 Therapeutics' P/S lags behind the industry despite a stro...

G1 Therapeutics' P/S lags behind the industry despite a strong price move. Its low P/S ratio is due to its forecast growth being lower than the wider industry. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio. The company needs a change of fortune for a higher P/S in the future.